DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib

Autor: Julie Dardare, Andréa Witz, Margaux Betz, Aurélie François, Laureline Lamy, Marie Husson, Jessica Demange, Marie Rouyer, Aurélien Lambert, Jean-Louis Merlin, Pauline Gilson, Alexandre Harlé

Publikováno v: Cell Death Discovery, Vol 10, Iss 1, Pp 1-10 (2024)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Therapeutic options for PDAC are primarily restricted to surgery in the early stages of the disease or chemotherapy in advanced disease. Only a subset of patients with

Externí odkaz: https://doaj.org/article/f812e69c8e8e400f9dc2fa11b2a0a91f

Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers

Autor: Pauline Gilson, Celso Pouget, Richard Belmonte, Smahane Fadil, Jessica Demange, Marie Rouyer, Julien Lacour, Margaux Betz, Julie Dardare, Andréa Witz, Jean-Louis Merlin, Alexandre Harlé

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)

Abstract Gene fusions and MET exon skipping drive oncogenesis in 8–9% and 3% of non-small cell lung cancers (NSCLC) respectively. Their detection are essential for the management of patients since they confer sensitivity to specific targeted therap

Externí odkaz: https://doaj.org/article/20406c264bfb4ec3b46fea9ad92a6877

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities

Autor: Julie Dardare, Andréa Witz, Jean-Louis Merlin, Agathe Bochnakian, Paul Toussaint, Pauline Gilson, Alexandre Harlé

Publikováno v: Pharmaceuticals, Vol 14, Iss 8, p 740 (2021)

Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with the worst prognosis despite a decade of efforts. Up to eighty percent of patients are managed at late stages with metastatic disease, in part due to a lack of diagnosis. The effe

Externí odkaz: https://doaj.org/article/48ae2811044f4d12b22f18372d07b9c3

CRISPR/Cas9-Mediated Knockdown Of BRCA1/2 Restores Response To Olaparib In Pancreatic Cancer Cell Lines

Autor: Andréa Witz, Julie Dardare, Aurélie Francois, Marie Husson, Marie Rouyer, Jessica Demange, Pauline Gilson, Jean-Louis Merlin, Alexandre Harlé

Background: Pancreatic cancer is one of the most aggressive diseases with a very poor outcome. Olaparib, a PARP inhibitor, as maintenance therapy showed benefits in patients with metastatic pancreatic adenocarcinoma bearing germline BRCA1/2 mutations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6550052b6feebaccffa78d652a7a346
https://doi.org/10.21203/rs.3.rs-1439273/v1

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma

Autor: Andréa Witz, Pauline Gilson, Julie Dardare, Alexandre Harlé, Jean-Louis Merlin

Publikováno v: International Journal of Molecular Sciences, Vol 21, Iss 3534, p 3534 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences, MDPI, 2020, 21 (10), pp.3534. ⟨10.3390/ijms21103534⟩

International audience; Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death worldwide. PDAC is an aggressive disease with an 11-month median overall survival and a five-year survival of less than 5%. Incidence of PDAC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d6ce8924dd67182d84c6bdd1f693b7f
https://www.mdpi.com/1422-0067/21/10/3534